Evidence map›Paper›PMID 32154221›Full record

ArticleFrontiers in chemistry2020

Strategy for Development of Site-Specific Ubiquitin Antibodies.

Ila van Kruijsbergen, Monique P C Mulder, Michael Uckelmann, Tibor van Welsem, John de Widt, Aldo Spanjaard, Heinz Jacobs, Farid El Oualid, Huib Ovaa, Fred van Leeuwen

Open access · goldAbstract read
In one paragraph

Article in Frontiers in chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Chemical proteomics approaches for protein post-translational modification studies.Biochimica et biophysica acta. Proteins and proteomics · 2024
    Review
  3. Article
  4. Review
  5. Article
  6. Site-specific ubiquitination: Deconstructing the degradation tag.Current opinion in structural biology · 2022
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Ila van KruijsbergenDivision of Gene Regulation, Netherlands Cancer Institute, Amsterdam, Netherlands.
Monique P C MulderLeiden Institute for Chemical Immunology, Oncode Institute, Leiden University Medical Center, Leiden, Netherlands.
Michael UckelmannDivision of Biochemistry, Netherlands Cancer Institute, Amsterdam, Netherlands.
Tibor van WelsemDivision of Gene Regulation, Netherlands Cancer Institute, Amsterdam, Netherlands.
John de WidtDivision of Biochemistry, Netherlands Cancer Institute, Amsterdam, Netherlands.
Aldo SpanjaardDivision of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Heinz JacobsDivision of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Farid El OualidUbiQ Bio BV, Amsterdam, Netherlands.
Huib OvaaLeiden Institute for Chemical Immunology, Oncode Institute, Leiden University Medical Center, Leiden, Netherlands.
Fred van LeeuwenDivision of Gene Regulation, Netherlands Cancer Institute, Amsterdam, Netherlands.
The Netherlands Cancer Institute · NLLeiden University Medical Center · NLUniQure (Netherlands) · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein ubiquitination is a key post-translational modification regulating a wide range of biological processes. Ubiquitination involves the covalent attachment of the small protein ubiquitin to a lysine of a protein substrate. In addition to its well-established role in protein degradation, protein ubiquitination plays a role in protein-protein interactions, DNA repair, transcriptional regulation, and other cellular functions. Understanding the mechanisms and functional relevance of ubiquitin as a signaling system requires the generation of antibodies or alternative reagents that specifically detect ubiquitin in a site-specific manner. However, in contrast to other post-translational modifications such as acetylation, phosphorylation, and methylation, the instability and size of ubiquitin-76 amino acids-complicate the preparation of suitable antigens and the generation antibodies detecting such site-specific modifications. As a result, the field of ubiquitin research has limited access to specific antibodies. This severely hampers progress in understanding the regulation and function of site-specific ubiquitination in many areas of biology, specifically in epigenetics and cancer. Therefore, there is a high demand for antibodies recognizing site-specific ubiquitin modifications. Here we describe a strategy for the development of site-specific ubiquitin antibodies. Based on a recently developed antibody against site-specific ubiquitination of histone H2B, we provide detailed protocols for chemical synthesis methods for antigen preparation and discuss considerations for screening and quality control experiments.

Indexed as

H2B-K123ubhistone H2Bmonoclonal antibodyPCNAubiquitin

Identifiers

PMID32154221
PMCPMC7047734
OpenAlexW3004981520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.